Successful treatment with nivolumab for SMARCA4 ‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report

We report the first case of SMARCA4‐deficient NSCLC with a high tumor mutation burden successfully treated with nivolumab. Anti‐PD‐1 antibodies might be a promising treatment strategy for patients with SMARCA4‐deficient NSCLC.

Source: Thoracic Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Tomoyuki Naito, Shigeki Umemura, Hiroshi Nakamura, Yoshitaka Zenke, Hibiki Udagawa, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Noriko Motoi, Keijyu Aokage, Masahiro Tsuboi, Genichiro Ishii, Koichi Goto Tags: CASE REPORT Source Type: research